Etiology of Pulmonary Infections in Human Immunodeficiency Virus–infected Inpatients Using Sputum Multiplex Real-time Polymerase Chain Reaction

Gary Maartens,1,6 Rulan Griesel,1 Felix Dube,2,a Mark Nicol,2,b and Marc Mendelson3

1Division of Clinical Pharmacology, Department of Medicine, 2Division of Medical Microbiology, Department of Pathology, and 3Division of Infectious Diseases and Human Immunodeficiency Virus Medicine, Department of Medicine, University of Cape Town, South Africa

Background. There are limited data on the etiology of respiratory infections in human immunodeficiency virus (HIV)–infected patients in resource-limited settings.

Methods. We performed quantitative multiplex real-time polymerase chain reaction (PCR) for Pneumocystis jirovecii and common bacterial and viral respiratory pathogens on sputum samples (spontaneous or induced) from a prospective cohort study of HIV-infected inpatients with World Health Organization danger signs and cough. Mycobacterial culture was done on 2 sputum samples, blood cultures, and relevant extrapulmonary samples.

Results. We enrolled 284 participants from 2 secondary-level hospitals in Cape Town, South Africa: median CD4 count was 97 cells/μL, 64% were women, and 38% were on antiretroviral therapy. One hundred forty-eight had culture-positive tuberculosis, 100 had community-acquired pneumonia (CAP), 26 had P. jirovecii pneumonia (PJP), and 64 had other diagnoses. Probable bacterial infection (>105 copies/mL) was detected in 133 participants; the prevalence was highest in those with CAP (52%). Haemophilus influenzae and Streptococcus pneumoniae were the commonest bacterial pathogens detected; atypical bacteria were uncommon. Viruses were detected in 203 participants; the prevalence was highest in those with PJP (85%). Human metapneumovirus was the commonest virus detected. Multiple coinfections were commonly detected.

Conclusions. Sputum multiplex PCR could become a useful diagnostic tool for bacterial respiratory infections in HIV-infected inpatients, but its value is limited as quantitative cutoffs have only been established for a few bacterial pathogens and validation has not been done in this patient population. We found a high prevalence of respiratory viruses, but it is unclear whether these viruses were causing infection as there are no accepted quantitative PCR cutoffs for diagnosing respiratory viral infections.

Keywords. HIV; bacterial pneumonia; Pneumocystis jirovecii pneumonia; tuberculosis; respiratory viral infections.
evidence on the role of viruses in HIV-associated pulmonary infections [1]. PJP is usually diagnosed clinically in low- and middle-income countries where facilities for bronchoscopy, sophisticated chest imaging, and microbiologic identification of \textit{P. jirovecii} are limited. However, a systematic review found poor diagnostic value of chest radiography, symptoms, signs, and basic laboratory tests for PJP [9]. Finally, differential diagnosis is further complicated by coinfections, which are common, especially in patients with PJP who often have coinfections with bacteria, cytomegalovirus, and/or TB [4, 9].

We determined the prevalence of TB on culture, and of respiratory viruses, bacteria, and \textit{P. jirovecii} on sputum multiplex polymerase chain reaction (PCR) in a prospective cohort study of HIV-infected inpatients with WHO danger signs and cough.

**METHODS**

We conducted a prospective cohort study to improve the evidence base for the WHO algorithm for the diagnosis of TB in seriously ill HIV-infected inpatients. This cohort has been reported in detail elsewhere [10]. In brief, the study was conducted in 2 regional hospitals in Cape Town, South Africa. Inclusion criteria were as follows: adults ($\geq$18 years of age), HIV-infected, screened within 24 hours of admission, current cough (any duration), and 1 or more WHO danger signs (respiratory rate $>30$ breaths/minute, heart rate $>120$ beats/minute, temperature $>39^\circ$C, and inability to walk unaided). Performance of sputum real-time multiplex PCR was an additional inclusion criterion for the current study (this was performed consecutively in the last 284 enrolled participants). Exclusion criteria were anti-TB therapy (either current, completed in the previous month, or interrupted in the past 6 months), exacerbation of congestive cardiac failure or chronic obstructive pulmonary disease, and being unable to produce a spontaneous or induced sputum sample. Cotrimoxazole prophylaxis and TB preventive therapy (limited to isoniazid in our national treatment program) were permitted.

Demographic and clinical data were recorded on standardized case record forms and entered into a database.

In keeping with WHO recommendations, all participants were commenced on empiric broad-spectrum antibiotics (typically ceftriaxone or amoxicillin-clavulanate) either at the referring clinic or on admission to the hospital emergency unit. Chest radiographs were retrospectively reviewed by a specialist radiologist who was blinded to the diagnoses.

Sputum induction, with hypertonic saline in an ultrasonic nebulizer, was done in participants unable to spontaneously produce sputum. One sputum sample was sent for quantitative, multiplex, real-time PCR with FTDResp33 (Fast-Track Diagnostics, Esch-sur-Alzet, Luxembourg) to identify potential respiratory pathogens (for details of sample preparation, see Dube et al [11]); there was no minimum volume required. Standard curves were derived using plasmid standards supplied by the manufacturer, and genome copy number was extrapolated from these curves. We used a cutoff of $>10^5$ copies/mL to distinguish between bacterial colonization and infection [12]. The limit of quantification ranged from $1.12 \times 10^3$ to $1.6 \times 10^6$ copies per reaction. Two sputum samples were sent for smear microscopy with auramine staining and liquid mycobacterial culture (BACTEC MGIT 960; Becton, Dickinson and Company, Franklin Lakes, New Jersey), and the Xpert MTB/RIF assay (Cepheid, Sunnyvale, California) was done on one sample. Sputum multiplex PCR was done after study completion, but Xpert MTB/RIF and mycobacterial cultures were done in real time and results made available to the treating clinicians. Mycobacterial blood culture (BacT/Alert MP; bioMérieux, Durham, North Carolina) was done in all participants. Where appropriate, other extrapulmonary specimens were sent for liquid mycobacterial culture.

Case definitions were as follows: TB, culture of \textit{Mycobacterium tuberculosis} from any site; PJP, $>1000$ copies/mL of \textit{P. jirovecii} DNA in sputum on real-time PCR [13, 14]; CAP, cough $\leq$14 days and pulmonary consolidation on chest radiograph confirmed by a radiologist.

**Statistical Analysis**

Analyses were performed using Stata version 13 (StataCorp, College Station, Texas) and EpiInfo version 7.1.4.0 software. Distributions of nonparametric data were expressed as median and interquartile range (IQR). Odds ratios (ORs) and 95% confidence intervals (CIs) were determined pairwise to compare proportions of pathogens by case definition, excluding participants who fulfilled both of the relevant case definitions.

**Ethics Approval**

The study was approved by the Human Research Ethics Committee, University of Cape Town. Eligible participants signed informed consent before enrollment into the study. Confused participants were enrolled and given the option to continue with participation once oriented; their data were removed from the study if consent was declined.

**RESULTS**

We enrolled 284 participants from January 2012 to October 2014; participant enrollment is shown in Figure 1. Almost all potentially eligible patients were able to produce an induced or spontaneous sputum sample. Participants’ baseline characteristics and diagnoses are shown in Table 1. Most participants had $>1$ WHO danger sign. Criteria for the 3 case definitions were fulfilled in 220 participants. Fifty participants fulfilled $>1$ case definition: 4 had CAP, PJP, and TB; 39 had CAP and TB; and 7 had CAP and PJP. The 64 participants with “other diagnoses” were medical officer discharge diagnoses of TB ($n = 4$), CAP ($n = 43$), and PJP ($n = 7$) that did not fulfill our case definitions, and 10 with miscellaneous conditions. Chest radiographs were not available for reporting in 32 participants.
Sputum Xpert MTB/RIF was performed on 281 participants, 147 of whom had culture-positive TB: Xpert was positive in 138 (5 false positives) with a sensitivity of 90.5% (95% CI, 84.5%–94.7%) and a specificity of 96.3% (95% CI, 91.5%–98.8%). The distribution of viruses and bacteria detected by sputum multiplex PCR is shown by diagnosis in Table 2. The prevalence of any bacteria >10⁵ copies/mL by case definition was as follows: CAP, 52% (95% CI, 42%–62%); PJP, 34% (95% CI, 19%–54%); and TB, 41% (95% CI, 34%–49%). Participants with CAP were more likely to have bacteria >10⁵ copies/mL than participants with PJP (OR, 3.06 [95% CI, 1.09–8.62]) or TB (OR, 1.94 [95% CI, 1.01–3.72]); this association was strengthened when limited to *Streptococcus pneumoniae* infection—CAP vs PJP (OR, 3.80 [95% CI, 0.47–30.76]) and CAP vs TB (OR, 6.06 [95% CI, 2.45–15.02]). Bacteria >10⁵ copies/mL were similar in participants with TB and PJP (OR, 1.49 [95% CI, 0.57–2.41]). The prevalence of any virus by case definition was as follows: CAP, 67% (95% CI, 57%–75%); PJP, 85% (95% CI, 66%–94%); and TB, 73% (95% CI, 65%–79%). Participants with PJP were more likely to have viruses than participants with CAP (OR, 7.12 [95% CI, 0.89–56.75]) or TB (OR, 2.35 [95% CI, 0.66–8.39]).

The distribution of genome copy number by virus is shown in box and whisker plots (Figure 2) for viruses detected in ≥10 participants (different species of coronavirus and parainfluenza virus were combined for this analysis). Detection of >1 pathogen was very common as illustrated by Figure 3A for all 284 participants and by Figure 3B for the 100 participants with CAP.

**DISCUSSION**

We found a high prevalence (47%) of probable bacterial infection on multiplex real-time PCR of sputum in a prospective cohort study of HIV-infected inpatients with WHO danger signs and cough. The proportion of bacterial infections, especially with *S. pneumoniae*, was higher in participants with CAP than in those with PJP or TB. Sputum multiplex PCR could become a useful diagnostic tool in HIV-infected inpatients who frequently receive antibiotics before or immediately on admission, as recommended by WHO: however, its value is currently limited as quantitative cutoffs have only been established for a few bacterial pathogens and validation has not been done in this patient population. We found an even higher prevalence (71%) of respiratory virus detection, but it is unclear whether these viruses were causing infection as there are no accepted quantitative PCR cutoffs for diagnosing respiratory virus infections. Viruses were more commonly detected in participants with PJP than in those with CAP or TB, but the confidence intervals were wide due to the relatively small number of participants with PJP.

Human metapneumovirus was the commonest viral pathogen detected in our cohort. Human metapneumovirus infection is predominantly seen in early childhood, but a South African epidemiological study showed that it was strongly associated with an increased risk of hospitalization among HIV-infected adults [15]. There are limited and contradictory data on the role of human metapneumovirus infection in HIV-infected adults: it was very uncommon in a Brazilian study of CAP in inpatients [16], but was commonly associated with respiratory infections in a Canadian outpatient study [17]. Cytomegalovirus was also

---

**Table 1. Baseline Characteristics and Diagnoses of 284 Human Immunodeficiency Virus–infected Inpatients With World Health Organization Danger Signs and Cough**

| Characteristic                              | No. (%)          |
|---------------------------------------------|------------------|
| **Female sex**                              | 182 (64)         |
| **Age, y, median (IQR)**                    | 36 (30–42)       |
| **CD4 count, cells/µL, median (IQR)**       | 97 (35–219)      |
| **Currently on ART**                        | 108 (38)         |
| **Duration on ART, y, median (IQR)**        | 2.4 (0.2–4.4)    |
| **Sputum induced**                          | 201 (71)         |
| **WHO danger signs**                        |                  |
| **Respiratory rate >30 breaths/min**        | 210 (74)         |
| **Heart rate >120 beats/min**               | 224 (79)         |
| **Temperature >39°C**                       | 46 (16)          |
| **Unable to walk unaided**                  | 146 (51)         |
| **Diagnoses**                               |                  |
| **TB culture positive from any site**       | 148 (52)         |
| **TB culture positive from sputum**         | 119 (42)         |
| **CAP**                                     | 100 (35)         |
| **PJP**                                     | 26 (9)           |
| **Other**                                   | 64 (23)          |

Data are presented as no. (%) unless otherwise indicated.

Abbreviations: ART, antiretroviral therapy; CAP, community-acquired pneumonia; IQR, interquartile range; PJP, Pneumocystis jiroveci pneumonia; TB, tuberculosis; WHO, World Health Organization.

*1 missing value.
*2 missing values.
commonly detected in our study and was detected in 17 of 26 participants with PJP. The role of cytomegalovirus as a respiratory pathogen is unclear in HIV-infected patients, especially in patients with PJP, who generally respond to therapy for PJP without an antiviral drug directed against cytomegalovirus [1].

The prevalence of *Haemophilus influenzae* in our participants with CAP was higher than is generally reported [1], but only 1 participant with CAP had *H. influenzae* type B detected.

In the expanded WHO algorithm for seriously ill HIV-infected patients, the use of antibiotics to cover both typical and atypical bacteria “should be considered” [18]. However, the role of atypical bacteria is uncertain in HIV-infected patients [1], partly due to the limitations of serological diagnosis in immunocompromised patients. A Kenyan study of inpatients with CAP found *Mycoplasma pneumoniae* in 2.7% of HIV-infected patients, and detected no cases of *Legionella* or *Chlamydia* [7]. By contrast, a South African study of inpatients (81.4% of whom were HIV seropositive) found *M. pneumoniae* in 17%, *Chlamydia pneumoniae* in 4.9%, and *Legionella pneumophila* in 0.9% [8]; the high prevalence of *M. pneumoniae* they reported could be explained if the study was

---

**Figure 2.** The distribution of genome copy number by virus is shown in box and whisker plots for viruses detected in ≥10 participants (different species of coronavirus and parainfluenza virus, respectively, were combined for this analysis). The horizontal line indicates the median, the box indicates the interquartile range, and the bars indicate the range.
done during an epidemic, which is likely as cyclical epidemics are a feature of *M. pneumoniae* epidemiology. We found that atypical bacteria were uncommon in seriously ill HIV-infected inpatients in our study using a molecular approach, which offers rapid diagnosis of atypical bacteria and should not be affected by immunostatus, unlike serology. South African surveys of inpatients (more than half of whom were HIV-infected) with severe respiratory illness found that *M. pneumoniae* was detected in 73 of 4703 (1.9%), which was not related to HIV status, *C. pneumoniae* in 11 of 2793 (0.4%), and *Legionella* species in 21 of 1805 (1.2%) using molecular approaches [19–21], supporting our finding that atypical bacteria are uncommon causes of respiratory infection in HIV-infected inpatients.

Our study has several limitations. First, we are unable to distinguish viral colonization from infection as there are no accepted quantitative PCR cutoffs for diagnosing respiratory virus infections. We are also unable to distinguish between viral upper and lower respiratory tract infections. Second, the cutoff we used for bacterial infection is derived from studies using quantitative culture but has not been widely validated for all bacterial pathogens [12], and has not been validated in HIV-infected patients with CAP, PJP, or TB. Third, the quantitative real-time PCR cutoff for *P. jirovecii* that we used as the reference standard for PJP was based on 2 studies that reported cutoffs of 1900 copies/mL [13] and 1300 copies/mL [14] to distinguish between colonization and infection. Because there is currently no accepted cutoff [22], we arbitrarily used 1000 copies/mL, which was within 0.3 log copies/mL of the cutoffs of the other 2 studies (the lowest value in participants meeting our case definition was 1858 copies/mL). However, a meta-analysis found that real-time PCR has a sensitivity of 97% and a specificity of 93% for the diagnosis of PJP in HIV-infected patients [22], indicating that this test is a reasonable reference standard. Fourth, our findings were in inpatients with WHO danger signs and cough, in a population with a high prevalence of TB, and with a high proportion requiring sputum induction; therefore, our findings may not be generalizable to other populations of HIV-infected patients. Sputum induction is a low-cost intervention that could be widely implemented in resource-limited settings to facilitate identification of respiratory pathogens, including *M. tuberculosis*.
In conclusion, we found a high prevalence of probable bacterial infection on multiplex PCR of sputum in HIV-infected inpatients with WHO danger signs and cough. More research needs to be done to establish quantitative cutoffs for bacterial and especially viral infection in patients with and without HIV infection, and to establish if multiplex PCR can safely guide therapeutic decisions or improve outcomes.

Notes

Author contributions. G. M., M. M., and M. N. designed the study, R. G. and F. D. performed data acquisition. G. M. and R. G. analyzed the data. G. M. produced the first draft. All authors revised the work, approved the final version, and take accountability for all aspects of the work.

Acknowledgments. Chest radiographic interpretation was done by Professor Hillel Goodman, Division of Radiology, Department of Radiation Medicine, University of Cape Town.

Financial support. This work was supported by the National Institutes of Health (grant number R01 AI 96735-01 International Research in Infectious Diseases including AIDS). G. M. was supported in part by the National Research Foundation of South Africa (grant-specific unique reference number 85810).

Potential conflicts of interest. M. N. reports grants from the National Institutes of Health during the conduct of the study. All other authors report no potential conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

References

1. Benito N, Moreno A, Miro JM, Torres A. Pulmonary infections in HIV-infected patients: an update in the 21st century. Eur Respir J 2012; 39:730–45.
2. Ford N, Shubber Z, McIntjes G, et al. Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis. Lancet HIV 2015; 2:e438–44.
3. Ford N, Matteelli A, Shubber Z, et al. TB as a cause of hospitalization and in-hospital mortality among people living with HIV worldwide: a systematic review and meta-analysis. J Int AIDS Soc 2016; 19:20714.
4. Wasserman S, Engel ME, Griesel R, Mendelson M. Burden of Pneumocystis pneumonia in HIV-infected adults in sub-Saharan Africa: a systematic review and meta-analysis. BMC Infect Dis 2016; 16:482.
5. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Available at: http://www.who.int/entity/hiv/pub/guidelines/keypopulations-2016/en/index.html. Accessed 18 December 2018.
6. Boyles TH, Griesel R, Stewart A, Mendelson M, Maartens G. Incremental yield and cost of urine determine TB-LAM and sputum induction in seriously ill adults with HIV. Int J Infect Dis 2018; 75:67–73.